Products
C1 esterase inhibitor is commercially available as a powder and solvent for the preparation of a solution for injection (Berinert, Cinryze). It has been approved in many countries since 1993.
Structure and properties
C1 esterase inhibitor is a glycoprotein with a molecular mass of 105 kDa, consisting of 478 amino acids and occurring naturally in blood plasma. It is derived from the plasma of healthy donors or produced as a recombinant protein by biotechnological methods.
Effects
C1 esterase inhibitor (ATC B06AC01) replaces the natural glycoprotein that is deficient in hereditary angioedema. C1 esterase inhibitor is responsible for inhibiting the complement system. It belongs to the serine protease inhibitors. The half-life is 36 hours.
Indications
For the treatment of an acute episode and for the prevention before surgery of hereditary angioedema.
Dosage
According to the SmPC. The drug is injected slowly intravenously.
Contraindications
- Hypersensitivity
- Capillary Leak Syndrome
For complete precautions, see the drug label.
Interactions
No information on drug-drug interactions is available.
Adverse effects
The most common possible adverse effects include hypersensitivity reactions, headache, dizziness, nausea, a rash, and injection site reactions.
